Quantitative Investment Management LLC Makes New $1.30 Million Investment in Halozyme Therapeutics, Inc. $HALO

Posted by Brian Himes on Sep 1st, 2026

Quantitative Investment Management LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 16,631 shares of the biopharmaceutical company’s stock, valued at approximately $1,301,000.

A number of other hedge funds have also recently made changes to their positions in the company. Empowered Funds LLC purchased a new stake in shares of Halozyme Therapeutics in the first quarter worth $755,000. Acadian Asset Management LLC bought a new position in Halozyme Therapeutics in the 1st quarter worth about $195,000. Hsbc Holdings PLC increased its stake in Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after acquiring an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares in the last quarter. Finally, Baird Financial Group Inc. raised its holdings in shares of Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 650 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Price Performance

HALO opened at $106.49 on Tuesday. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock has a market capitalization of $12.09 billion, a P/E ratio of 31.79, a PEG ratio of 0.42 and a beta of 0.85. The stock has a 50-day moving average price of $87.76 and a 200-day moving average price of $74.93. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $109.66.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.Halozyme Therapeutics’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period last year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts predict that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This represents a 33.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $79,987,320.40. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 42,478 shares of company stock worth $3,767,304 over the last ninety days. Insiders own 2.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on HALO. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. UBS Group reaffirmed a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Morgan Stanley dropped their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings cut shares of Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, August 14th. Finally, Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $91.20.

Check Out Our Latest Research Report on HALO

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.